SCHEMBL3104646

SCHEMBL3104646

Cc1n[nH]c2nccc(Oc3cnc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)nc3)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 20/20 0.35
MERTK Q12866 16/20 0.35
MET P08581 12/20 0.35
TYRO3 Q06418 6/20 0.35
AURKA O14965 1/20 0.34
RIPK2 O43353 1/20 0.34
ABCB11 O95342 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
NTRK1 P04629 1/20 0.34
LCK P06239 1/20 0.34
PGR P06401 1/20 0.34
LYN P07948 1/20 0.34
RET P07949 1/20 0.34
CHRM2 P08172 1/20 0.34
HCK P08631 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
KIT P10721 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3108895 0.92 AXL (0.40) AXLMERTKMETTYRO3AURKA
SCHEMBL3112277 0.91 AXL (0.37) AXLMERTKMETTYRO3AURKA
SCHEMBL3113836 0.88 MET (0.34) AXLMERTKMETTYRO3RET
SCHEMBL3100072 0.87 AXL (0.40) AXLMERTKMETTYRO3KDR
SCHEMBL3102184 0.87 AXL (0.38) AXLMERTKMETTYRO3AURKA
SCHEMBL3101269 0.87 AXL (0.37) AXLMERTKMETTYRO3AURKA
SCHEMBL3099850 0.87 AXL (0.33) AXLMERTKMETTYRO3AURKA
SCHEMBL3101845 0.86 MET (0.42) AXLMERTKMETTYRO3RET
SCHEMBL3114395 0.86 MET (0.37) AXLMERTKMETTYRO3RET
SCHEMBL3113385 0.86 AXL (0.40) AXLMERTKMETTYRO3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US claimed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 AXL 117/4885MERTK 285/4885MET 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.